Quantcast

Helix BioMedix, Inc. Reports 2012 Financial Results

June 20, 2013

New Stockholder Communication Plan Announced

Bothell, Washington (PRWEB) June 20, 2013

Helix BioMedix, Inc. (HXBM), a developer of bioactive peptides, today announced that it had posted to its website at http://www.helixbiomedix.com/investors.html an update to its stockholders along with the company´s audited year-end 2012 financial results and unaudited first quarter 2013 financial results.

The company intends to disseminate updates, financial results and other important information for stockholders by posting such information on its website at http://www.helixbiomedix.com/investors.html on a regular basis. Stockholders should monitor the company´s website on a regular basis to obtain the most current and accurate information about the company.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of structurally diverse bioactive peptides and patents covering hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Apothederm, SmartPeptides, MD3 Copper, HBCeuticals and Striking are registered trademarks of Helix BioMedix, Inc.. SmartPeptide, Skin Care Science and Cerakine are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company´s website at http://www.helixbiomedix.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10856656.htm


Source: prweb



comments powered by Disqus